|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2010
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Krystexxa
|
|
gptkbp:chemical_formula
|
C_60 H_90 N_16 O_20 S_4
|
|
gptkbp:clinical_trial
|
Phase 3
PEARL study
CRYSTAL study
KOGNITIVE study
|
|
gptkbp:clinical_use
|
reduce uric acid levels
|
|
gptkbp:contraindication
|
G6 PD deficiency
|
|
gptkbp:developed_by
|
gptkb:Horizon_Therapeutics
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:duration
|
every 2 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Krystexxa
|
|
gptkbp:indication
|
refractory chronic gout
|
|
gptkbp:ingredients
|
pegloticase
|
|
gptkbp:invention
|
patented
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
gptkb:Krystexxa
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
uricase enzyme
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:research_focus
|
rheumatology
biologics
immunology
gout treatment
chronic hyperuricemia
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
vomiting
urticaria
diarrhea
rash
anaphylaxis
infusion reactions
gout flares
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:used_for
|
chronic gout
|
|
gptkbp:weight
|
1,000 k Da
|
|
gptkbp:bfsParent
|
gptkb:Horizon_Therapeutics
|
|
gptkbp:bfsLayer
|
5
|